-
公开(公告)号:US10144738B2
公开(公告)日:2018-12-04
申请号:US15437618
申请日:2017-02-21
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: C07D487/04 , A61K31/4985
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein A, A′ and A″ are independently O, C═O, etc.; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, etc.; R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), etc.; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US12129256B2
公开(公告)日:2024-10-29
申请号:US17939375
申请日:2022-09-07
Applicant: PFIZER INC.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
CPC classification number: C07D487/04 , A61K31/4985
Abstract: A compound having the structure:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.-
公开(公告)号:US20200172537A1
公开(公告)日:2020-06-04
申请号:US16638271
申请日:2018-08-09
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Fensome , Dafydd Rhys Owen , Matthew Frank Brown , Matthew Merrill Hayward , Felix Vajdos , Li Huang Xing , Stephen Wayne Wright
IPC: C07D471/04 , C07D519/00 , C07D401/14 , C07D405/14 , C07D401/04
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US11472809B2
公开(公告)日:2022-10-18
申请号:US17014533
申请日:2020-09-08
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
-
公开(公告)号:US11254668B2
公开(公告)日:2022-02-22
申请号:US16638271
申请日:2018-08-09
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Fensome , Dafydd Rhys Owen , Matthew Frank Brown , Matthew Merrill Hayward , Felix Vajdos , Li Huang Xing , Stephen Wayne Wright
IPC: C07D471/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D519/00
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US10822341B2
公开(公告)日:2020-11-03
申请号:US16181596
申请日:2018-11-06
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: C07D487/04
Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US20190292157A1
公开(公告)日:2019-09-26
申请号:US16380256
申请日:2019-04-10
Applicant: Pfizer Inc.
Inventor: Agustin Casimiro-Garcia , Jeffrey Scott Condon , Andrew Christopher Flick , Ariamala Gopalsamy , Steven J. Kirincich , John Paul Mathias , Joseph Walter Strohbach , Jason Shaoyun Xiang , Li Huang Xing , Xiaolun Wang
IPC: C07D239/42 , A61P35/00 , A61P1/04 , A61P1/00 , C07D405/10 , A61K31/505 , C07D401/12 , C07D241/14 , C07D239/28 , C07D403/12
Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号:US10308615B2
公开(公告)日:2019-06-04
申请号:US15574625
申请日:2016-05-16
Applicant: Pfizer Inc.
Inventor: Agustin Casimiro-Garcia , Jeffrey Scott Condon , Andrew Christopher Flick , Ariamala Gopalsamy , Steven J. Kirincich , John Paul Mathias , Joseph Walter Strobach , Jason Shaoyun Xiang , Li Huang Xing , Xiaolun Wang
IPC: C07D239/42 , C07D401/12 , C07D403/12 , A61K31/505 , C07D239/28 , C07D241/14 , A61P1/00 , A61P1/04 , A61P35/00 , C07D405/10
Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号:US20180148420A1
公开(公告)日:2018-05-31
申请号:US15574625
申请日:2016-05-16
Applicant: Pfizer Inc.
Inventor: Agustin Casimiro-Garcia , Jeffrey Scott Condon , Andrew Christopher Flick , Ariamala Gopalsamy , Steven J. Kirincich , John Paul Mathias , Joseph Walter Strobach , Jason Shaoyun Xiang , Li Huang Xing , Xiaolun Wang
IPC: C07D239/42 , A61P1/00 , A61P1/04 , A61P35/00 , C07D401/12 , C07D403/12 , C07D405/10
CPC classification number: C07D239/42 , A61K31/505 , A61P1/00 , A61P1/04 , A61P35/00 , C07D239/28 , C07D241/14 , C07D401/12 , C07D403/12 , C07D405/10
Abstract: Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
-
-
-
-
-
-
-